• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Severino Michael

    5/13/25 6:00:29 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    SEVERINO MICHAEL

    (Last) (First) (Middle)
    1000 MYLAN BOULEVARD

    (Street)
    CANONSBURG PA 15317

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    Viatris Inc [ VTRS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Kevin D. Macikowski, by power of attorney 05/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    More analyst ratings

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Viatris with a new price target

      Goldman initiated coverage of Viatris with a rating of Neutral and set a new price target of $10.00

      6/6/25 8:33:51 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Viatris with a new price target

      Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00

      7/19/24 8:34:32 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris downgraded by BofA Securities with a new price target

      BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously

      10/23/23 7:20:20 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      5/14/25 6:00:11 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      10/25/24 4:30:03 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

      PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br

      6/12/25 4:30:00 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

      MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapies No Evidence of Tachyphylaxis Was Observed In This Study Over The 6-Week Period Study Was Conducted Under FDA Special Protocol Assessment And Fast-Track Designation PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluati

      6/2/25 8:00:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada

      ETOBICOKE, ON, May 27, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia1. It is estimated that 25% to 30% of individuals with schizophrenia meet the criteria for treatment-resistant schizophrenia.1 Dr. Ofer Agid, Medical Head of Ambulatory Services in the Schizophrenia Division at the Cent

      5/27/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viatris Inc.

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      11/12/24 1:41:20 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

      SC 13G/A - Viatris Inc (0001792044) (Subject)

      2/13/24 5:17:31 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Viatris Inc.

      SC 13G - Viatris Inc (0001792044) (Subject)

      2/9/24 1:10:51 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Viatris Inc.

      SCHEDULE 13G - Viatris Inc (0001792044) (Subject)

      5/14/25 10:45:26 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

      SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

      5/8/25 10:20:37 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Viatris Inc.

      10-Q - Viatris Inc (0001792044) (Filer)

      5/8/25 9:21:14 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care